95 related articles for article (PubMed ID: 3156203)
1. Medroxyprogesterone acetate does not perturb the profile of steroid metabolites in urine during pregnancy.
Yovich JL; Willcox DL; Wilkinson SP; Poletti VM; Hähnel R
J Endocrinol; 1985 Mar; 104(3):453-9. PubMed ID: 3156203
[TBL] [Abstract][Full Text] [Related]
2. Changes in total and free concentrations of steroid hormones in the plasma of women throughout pregnancy: effects of medroxyprogesterone acetate in the first trimester.
Willcox DL; Yovich JL; McColm SC; Schmitt LH
J Endocrinol; 1985 Nov; 107(2):293-300. PubMed ID: 2933480
[TBL] [Abstract][Full Text] [Related]
3. Specific and sensitive determination of medroxyprogesterone acetate in human serum by gas chromatography-mass spectrometry.
Dikkeschei LD; van Veelen H; Nagel GT; Willemse PH; Wolthers BG
J Chromatogr; 1985 Nov; 345(1):1-10. PubMed ID: 2935550
[TBL] [Abstract][Full Text] [Related]
4. Initiation of parturition and lactation in the sow: effects of delaying parturition with medroxyprogesterone acetate.
Whitely JL; Hartmann PE; Willcox DL; Bryant-Greenwood GD; Greenwood FC
J Endocrinol; 1990 Mar; 124(3):475-84. PubMed ID: 2139693
[TBL] [Abstract][Full Text] [Related]
5. Comparison of mass spectrometry and radioimmunoassay to measure medroxyprogesterone acetate in patients with endometrial cancer.
Kärkkäinen J; Vesterinen E; Stenman UH; Adlercreutz H; Nieminen U; Widholm O
Eur J Cancer; 1990; 26(9):975-7. PubMed ID: 2149024
[TBL] [Abstract][Full Text] [Related]
6. Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation.
Johansson ED; Johansen PB; Rasmussen SN
Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):311-7. PubMed ID: 2943134
[TBL] [Abstract][Full Text] [Related]
7. The plasma concentration of medroxyprogesterone acetate and ovarian function during treatment with medroxyprogesterone acetate in 5 and 10 mg doses.
Wikström A; Green B; Johansson ED
Acta Obstet Gynecol Scand; 1984; 63(2):163-8. PubMed ID: 6233840
[TBL] [Abstract][Full Text] [Related]
8. MPA given orally during the first trimester for threatened miscarriage carries no specific risk for foetal abnormalities albeit the rate is higher than non-threatened pregnancies.
Yovich JL; Mariappen U; Hinchliffe PM; Dhaliwal SS; Keane KN
Reprod Biol; 2020 Sep; 20(3):424-432. PubMed ID: 32389607
[TBL] [Abstract][Full Text] [Related]
9. Mass spectrometric and high-performance liquid chromatographic studies of medroxyprogesterone acetate metabolites in human plasma.
Sturm G; Häberlein H; Bauer T; Plaum T; Stalker DJ
J Chromatogr; 1991 Jan; 562(1-2):351-62. PubMed ID: 1827448
[TBL] [Abstract][Full Text] [Related]
10. Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects.
Yovich JL; Turner SR; Draper R
Teratology; 1988 Aug; 38(2):135-44. PubMed ID: 3175947
[TBL] [Abstract][Full Text] [Related]
11. Medroxyprogesterone acetate in human serum.
Mathrubutham M; Fotherby K
J Steroid Biochem; 1981 Aug; 14(8):783-6. PubMed ID: 6457936
[TBL] [Abstract][Full Text] [Related]
12. Plasma concentrations of medroxyprogesterone acetate and megesterol acetate during long-term follow-up in patients treated for metastatic breast cancer.
Miller AA; Becher R; Schmidt CG
J Cancer Res Clin Oncol; 1988; 114(2):186-90. PubMed ID: 2965155
[TBL] [Abstract][Full Text] [Related]
13. Embryotoxicity of a single dose of medroxyprogesterone acetate (MPA) and maternal serum MPA concentrations in cynomolgus monkey (Macaca fascicularis).
Prahalada S; Carroad E; Cukierski M; Hendrickx AG
Teratology; 1985 Dec; 32(3):421-32. PubMed ID: 2934853
[TBL] [Abstract][Full Text] [Related]
14. Control of illegal medroxyprogesterone acetate-application in veal calves by residue analysis in adipose tissue using HPLC/RIA methods.
Rapp M; Meyer HH
Food Addit Contam; 1989; 6(1):59-69. PubMed ID: 2521473
[TBL] [Abstract][Full Text] [Related]
15. Serum progesterone and estradiol in pregnant women selected for progestagen treatment.
Dubin NH; Moszkowski EF; Kavoussi KM; Ward MM; Ances IG
Int J Fertil; 1979; 24(2):86-93. PubMed ID: 40914
[TBL] [Abstract][Full Text] [Related]
16. Serum progesterone distribution in normal pregnancies compared to pregnancies complicated by threatened miscarriage from 5 to 13 weeks gestation: a prospective cohort study.
Ku CW; Allen JC; Lek SM; Chia ML; Tan NS; Tan TC
BMC Pregnancy Childbirth; 2018 Sep; 18(1):360. PubMed ID: 30185145
[TBL] [Abstract][Full Text] [Related]
17. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
de Greef WJ; Dullaart J; Zeilmaker GH
J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105
[TBL] [Abstract][Full Text] [Related]
18. [Current concepts in the management of abortion. IV. Results gained in the treatment of abortion using new progestational steroids].
Alvarez-Bravo A; Vázquez E; González-Ramos M
Gac Med Mex; 1968 Oct; 98(10):1275-87. PubMed ID: 5729387
[No Abstract] [Full Text] [Related]
19. Effect of gestational sex steroid exposure on limb development and endochondral ossification in the pregnant C57Bl/6J mouse: I. Medroxyprogesterone acetate.
Carbone JP; Figurska K; Buck S; Brent RL
Teratology; 1990 Aug; 42(2):121-30. PubMed ID: 2145652
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients.
Etienne MC; Milano G; Frenay M; Renee N; Francois E; Thyss A; Schneider M; Namer M
J Clin Oncol; 1992 Jul; 10(7):1176-82. PubMed ID: 1535103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
